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The search for a minimally invasive solution to improve the status of a pathologic joint surface and allow a fast return to full activity is highly desirable. In this landscape, a novel promising injective treatment is platelet-rich plasma (PRP), a blood derivative characterized by a higher platelet concentration than that of whole blood. When activated, platelets release a group of bioactive molecules that ultimately promote cellular recruitment, growth, and morphogenesis, and modulate inflammation as well [7] . Therefore, PRP is an appealing biological approach to favour the healing of tissues, such as cartilage, otherwise doomed by a low healing potential. This led to the wide use of PRP, which shows promise to address joint degeneration processes in a minimally trials. It is also likely that many aspects such as cellularity, activation modality, better patient and disease indication need to be further explored to improve the potential of this biological treatment and that future developments will optimize PRP results and lead to a better outcome. However, besides these common considerations which are mainly focused on product variability, another interesting observation may be made about the general concept of "platelet-derived growth factor" injections. The lack of difference in the latter study was not due to a lack of PRP effect, which was similar to previous studies in terms of improvement and duration, but to the different response of the patients to viscosupplementation. In fact, whereas in a previous un-blinded comparison HA presented a lower effect, drastically dropping at 6 months [8] , when patients were blinded (and aware of the possibility of receiving "growth factors"), viscosupplementation offered both higher and longer lasting results, overlapping to those of PRP [4] , thus supporting a significant placebo effect.
Research on "the powerful placebo" started in 1955 with a provocative article by Beecher [1] ascribing 35 % of the clinical benefit to this effect, and over the last 60 years effects have been documented on all subjective outcomes (not just patient-centred, such as pain, stiffness, selfreported function, but also observer-centred), whereas the placebo has been seen as ineffective on most objective outcomes [9] . Thus, the value of the placebo effect is significant mainly for patients' symptoms and distress, which are the principal treatment targets in patients with OA, a condition where the pathology does not always correlate with symptoms [2] , and may account for a large part of the documented PRP improvement.
PRP actually meets the requirements of an ideal placebo. Response to a placebo is irrespective of IQ [3] , thus possibly affecting all patients, and the magnitude of the effect is determined largely by what patients are told about their treatment and by their expectations [2] , which are considerably high when dealing with the fashionable "growth factor" PRP therapy. Besides response expectancy, branding and cost (treatment perceived as "high class"), novelty of the treatment, and route of delivery (needling is one of the most powerful, especially when performed repeatedly in injection cycles) [3] further support the marked components of the placebo effect in the overall improvement perceived by patients undergoing PRP i.a. injections.
PRP is a promising innovative approach, and increasing research efforts will provide a better understanding about its action mechanism, as well as the most suitable procedure to target specific patients and disease phases, which would probably optimize PRP results in the clinical practice. Nonetheless, it is important to remember the marked psychological effects related to this new and fashionable treatment, and future studies will need to couple the commonly used subjective scores with some objective outcome measures, to better define the placebo component of PRP and understand the real potential of this biological approach for the treatment of cartilage degeneration and knee OA.
